Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

868 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Up-titration of allopurinol in patients with gout.
Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, Riches PL, Ralston SH, MacDonald TM; FAST study group. Jennings CG, et al. Among authors: de caterina r. Semin Arthritis Rheum. 2014 Aug;44(1):25-30. doi: 10.1016/j.semarthrit.2014.01.004. Epub 2014 Jan 23. Semin Arthritis Rheum. 2014. PMID: 24560169
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, Hallas J, Hawkey CJ, Ralston S, Walters M, Webster J, McMurray J, Perez Ruiz F, Jennings CG; Members of the FAST Study Group. MacDonald TM, et al. Among authors: de caterina r. BMJ Open. 2014 Jul 10;4(7):e005354. doi: 10.1136/bmjopen-2014-005354. BMJ Open. 2014. PMID: 25011991 Free PMC article. Clinical Trial.
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Among authors: de caterina r. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI; Coordinating Committee. De Caterina R, et al. J Am Coll Cardiol. 2012 Apr 17;59(16):1413-25. doi: 10.1016/j.jacc.2012.02.008. J Am Coll Cardiol. 2012. PMID: 22497820 Free article. Review.
Anticoagulants in heart disease: current status and perspectives.
De Caterina R, Husted S, Wallentin L, Agnelli G, Bachmann F, Baigent C, Jespersen J, Kristensen SD, Montalescot G, Siegbahn A, Verheugt FW, Weitz J. De Caterina R, et al. Eur Heart J. 2007 Apr;28(7):880-913. doi: 10.1093/eurheartj/ehl492. Epub 2007 Apr 10. Eur Heart J. 2007. PMID: 17426080 Free article. No abstract available.
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology.
Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R. Kuliczkowski W, et al. Among authors: de caterina r. Eur Heart J. 2009 Feb;30(4):426-35. doi: 10.1093/eurheartj/ehn562. Epub 2009 Jan 27. Eur Heart J. 2009. PMID: 19174428 Review.
868 results